Little DDP-4 Comp for Januvia

[Anonymous]

Alogliptin (SYR-322), similar in class to Merck’s (MRK) blockbuster DPP4-inhibitor Januvia (sitagliptin), lowers blood glucose by inhibiting the pancreatic hormone glucagon. Though available in its home market since 2010, U.S. marketing approval has stalled, pending outcome of additional cardiovascular safety trials.

Read more: http://www.bnet.com/blog/sec-filings/inside-takeda-8217s-drug-drought-

 

[Anonymous]

Alogliptin (SYR-322), similar in class to Merck’s (MRK) blockbuster DPP4-inhibitor Januvia (sitagliptin), lowers blood glucose by inhibiting the pancreatic hormone glucagon. Though available in its home market since 2010, U.S. marketing approval has stalled, pending outcome of additional cardiovascular safety trials.

Read more: http://www.bnet.com/blog/sec-filings/inside-takeda-8217s-drug-drought-

I am so concerned. Another me too dpp4 inhibitor that was actually rejected by the FDA the first time around. At least it doesnt cause bladder cancer though.

 

[Anonymous]

Soon the DDP-4 market will be like the ACEI market a decade ago.